The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Finally, in late-stage PDAC with germline mutation in BRCA1 or BRCA2 (~7.5% of the patients), the PARP inhibitor olaparib could extend progression free survival but not overall survival (8).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [8]
In the citing paper
“a pivotal clinical trial in patients with PDAC and germline BRCA1/2 mutations established the benefit of administering an orally bioavailable PARP inhibitor on improved progression free survival (PFS). This led to the approval of targeted therapy in this setting87.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,002
Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer
Rocha, F. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09367-9 · Cited by 19
Pancreas cancer: Therapeutic trials in metastatic disease
Smithy, J. W., & O'Reilly, E. M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26359 · Cited by 17
Self-citationSadat, S. M. A., de Paiva, I. M., Shire, Z., Sanaee, F., Morgan, T. D. R., Paladino, M., Karimi‐Busheri, F., Mani, R. S., Martin, G. R., Jirik, F. R., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.034 · Cited by 18
Laish, I., Friedman, E., Levi, G. R., Kedar, I., Katz, L. H., Levi, Z., Halpern, N., Parnasa, S. Y., Shtaya, A. A., Half, E., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06258-9 · Cited by 18
Su, Y., Ng, C. T., Jan, Y., Hsieh, Y., Wu, C.-L., & Tan, K. T. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s317514 · Cited by 17
Wieme, G., Král, J., Rosseel, T., Zemánková, P., Parton, B., Vočka, M., Heetvelde, M. V., Kleiblová, P., Blaumeiser, B., Soukupová, J., et al. (2021) · Cancers · doi:10.3390/cancers13174430 · Cited by 19
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology
Shah, S. M., Demidova, E. V., Lesh, R. W., Hall, M. J., Daly, M. B., Meyer, J. E., Edelman, M. J., & Arora, S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102337 · Cited by 17
Self-citationLundy, J., McKay, O., Croagh, D., & Ganju, V. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00437 · Cited by 18
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Sáez, M. A., Barquero-Pozanco, I., del Hierro-Marlasca, L., Castro-Martinez, P. D., Romero-Bazán, A., Álvarez-Mon, M. Á., Monserrat, J., et al. (2022) · Cancers · doi:10.3390/cancers14081866 · Cited by 18
Combination immunotherapy for pancreatic cancer: challenges and future considerations
Gössling, G. C. D. L., Zhen, D. B., Pillarisetty, V. G., & Chiorean, E. G. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2120471 · Cited by 18
Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
Bailey, P. J., Zhou, X., An, J., Peccerella, T., Hu, K., Springfeld, C., Büchler, M. W., & Neoptolemos, J. P. (2023) · Function · doi:10.1093/function/zqad011 · Cited by 18
The modification role and tumor association with a methyltransferase: KMT2C
Jiao, Y., Lv, Y., Liu, M., Liu, Y., Han, M., Xiong, X., Zhou, M., Zhong, J., Kang, X., & Su, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444923 · Cited by 21
Sarno, F., Tenorio, J. A., Perea, S., Medina, L., Pazo-Cid, R., Martel, I. J., García‐Carbonero, R., Feliú, J., Guillén‐Ponce, C., Lopez-Casas, P. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4026 · Cited by 17
Habaka, M., Daly, G. R., Shinyanbola, D., Alabdulrahman, M., McGrath, J., Dowling, G. P., Hehir, C. M., Huang, H. Y. R., Hill, A. D. K., Varešlija, D., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01669-z · Cited by 17
Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer
Sugarman, R., Patel, R., Sharma, S., Plenker, D., Tuveson, D. A., & Saif, M. W. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1637417 · Cited by 17
Shimmura, H., Kuramochi, H., Jibiki, N., Katagiri, S., Nishino, T., & Araida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz141 · Cited by 17
Ishii, Y., Serikawa, M., Tsuboi, T., Kawamura, R., Tsushima, K., Nakamura, S., Hirano, T., Fukiage, A., Mori, T., Ikemoto, J., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11020238 · Cited by 17
Pancreatic cancer pathology viewed in the light of evolution
Noë, M., Hong, S., Wood, L. D., Thompson, E. D., Roberts, N. J., Goggins, M., Klein, A. P., Eshleman, J. R., Kern, S. E., & Hruban, R. H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09953-z · Cited by 17
Inherited Pancreatic Cancer Syndromes and High-Risk Screening
Biller, L. H., Wolpin, B. M., & Goggins, M. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.002 · Cited by 19
The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Low, R. R. J., Lim, W., Nguyen, P. M., Lee, B., Christie, M., Burgess, A. W., Gibbs, P., Grimmond, S. M., Hollande, F., & Putoczki, T. L. (2021) · Cancers · doi:10.3390/cancers13194979 · Cited by 17
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
Raufi, A. G., Liguori, N. R., Carlsen, L., Parker, C., Borrero, L. J. H., Zhang, S., Tian, X., Louie, A. D., Zhou, L., Seyhan, A. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751568 · Cited by 18
Silva, S. B., Wanderley, C. W. S., & Colli, L. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826577 · Cited by 17
Li, L., Zhong, S., Li, R., Liang, N., Zhang, L., Shen, X., Xu, X., Chen, X., Chen, S., Tao, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155869 · Cited by 18
Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
Maresca, L., Stecca, B. A., & Carrassa, L. (2022) · Cells · doi:10.3390/cells11091466 · Cited by 17
Yamakawa, K., Koyanagi‐Aoi, M., Uehara, K., Masuda, A., Yanagimoto, H., Toyama, H., Fukumoto, T., Kodama, Y., & Aoi, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266620 · Cited by 16
Businello, G., Angerilli, V., Lonardi, S., Bergamo, F., Valmasoni, M., Farinati, F., Savarino, E. V., Spolverato, G., & Fassan, M. (2022) · Updates in Surgery · doi:10.1007/s13304-022-01330-5 · Cited by 18
Zhang, C., Atri, P., Nallasamy, P., Parte, S. C., Rauth, S., Nimmakayala, R. K., Marimuthu, S., Chirravuri‐Venkata, R., Bhatia, R., Halder, S., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215922 · Cited by 17
Cui, J., Fu, Q., Chen, X., Wang, Y., Li, Q., Wang, F., Li, Z., Dai, G., Wang, Y., Zhang, H., et al. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000155 · Cited by 17
Lumeau, A., Béry, N., Francès, A., Gayral, M., Labrousse, G., Ribeyre, C., Lopez, C., Nevot, A., Kaoutari, A. E., Hanoun, N., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-22-3219 · Cited by 23
Walmsley, C. S., Jonsson, P., Cheng, M. L., McBride, S. M., Kaeser, C., Vargas, H. A., Laudone, V. P., Taylor, B. S., Kappagantula, R. L., Baez, P., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00526-9 · Cited by 17
New Therapeutic Options for BRCA Mutant Patients
Ghanem, A., & Domchek, S. M. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-082523-083843 · Cited by 17
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
Wang, Y., Zhang, J., Wu, X., Huang, L., Xiao, W., & Guo, C. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02642 · Cited by 18
Omics Approaches in Pancreatic Adenocarcinoma
González‐Borja, I., Viúdez, A., Goñi, S., Santamaría, E., Carrasco‐García, E., Pérez‐Sanz, J., Hernández-García, I., Elarre, P. S., Arrazubi, V., Oyaga-Iriarte, E., et al. (2019) · Cancers · doi:10.3390/cancers11081052 · Cited by 16
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07481-1 · Cited by 19
DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment
Burdak‐Rothkamm, S., & Rothkamm, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.011 · Cited by 17
Fountzilas, E., Eliades, A., Koliou, G.-A., Achilleos, A., Loizides, C., Tsangaras, K., Pectasides, D. G., Sgouros, J., Papakostas, P., Rallis, G., et al. (2021) · Cancers · doi:10.3390/cancers13020198 · Cited by 17
Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
Luchini, C., Grant, R. C., Scarpa, A., & Gallinger, S. (2021) · Gut · doi:10.1136/gutjnl-2020-323805 · Cited by 17
Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer
Kuo, K., Hsiao, P., Chang, W., Chuang, S., Yang, Y.-H., Wuputra, K., Ku, C., Pan, J.-B., Li, C.-P., Kato, K., et al. (2021) · Cancers · doi:10.3390/cancers13153920 · Cited by 17
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
Barros, A., Pulido, C., Machado, M., Brito, M. J., Couto, N., Sousa, O., Melo, S. A., & Mansinho, H. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5290 · Cited by 20
The Utility of Endoscopic-Ultrasonography-Guided Tissue Acquisition for Solid Pancreatic Lesions
Tanaka, H., & Matsusaki, S. (2022) · Diagnostics · doi:10.3390/diagnostics12030753 · Cited by 18
Sun, G., Miao, G., Li, Z., Zheng, W., Zhou, C., Sun, G., Cao, H., Li, Z., & Tang, W. (2022) · Journal of Oncology · doi:10.1155/2022/6988923 · Cited by 18
Homeostases of epidermis and hair follicle, and development of basal cell carcinoma
Jaiswal, A., & Singh, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188795 · Cited by 19
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
Rudloff, U. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2134346 · Cited by 17
Hammel, P. R., Vitellius, C., Boisteau, É., Wisniewski, M., Colle, E., Hilmi, M., d’Engremont, C., Granier, S., Turpin, A., de Mestier, L., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937949 · Cited by 16
Self-citationInnovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
Tremmel, R., Hübschmann, D., Schaeffeler, E., Pirmann, S., Fröhling, S., & Schwab, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001049 · Cited by 17
Lee, S., Kim, J., Jeong, E., & Myung, K. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103887 · Cited by 16
Recent advances in immunotherapy for pancreatic cancer
Chi, J., Patel, R., Rehman, H., Goyal, S. P., & Saif, M. W. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.90 · Cited by 15
Cerniglia, M., Xiu, J., Grothey, A., Pishvaian, M. J., Baca, Y., Hwang, J. J., Marshall, J. L., VanderWalde, A. M., Shields, A. F., Lenz, H.-J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0879 · Cited by 17
Li, S., Li, T., Dai, H., Gong, X., Zhuo, Y., Xiang, H., Zhao, Y., Gao, Q., & Deng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.718871 · Cited by 19
Walsh, E. M., Mangini, N. S., Fetting, J. H., Armstrong, D. K., Chan, I. S., Connolly, R. M., Fiallos, K., Lehman, J., Nunes, R., Petry, D., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.12.007 · Cited by 18
Sun, H., Du, S., Li, Y.-Y., Deng, G., & Zeng, F. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.75 · Cited by 16
Leal, T. A. B., Sharifi, M. N., Chan, N., Wesolowski, R., Turk, A. A., Bruce, J. Y., O'Regan, R. M., Eickhoff, J. C., Barroilhet, L. M., Malhotra, J. D., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4724 · Cited by 18
Golesworthy, B., Wang, Y., Tanti, A., Pacis, A., Romero, J. M., Cuggia, A., Domecq, C., Bourdel, G., Denroche, R. E., Jang, G. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860767 · Cited by 16
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives
Geyik, Ö. G., Anichini, G., Ulukaya, E., Marra, F., & Raggi, C. (2022) · Cells · doi:10.3390/cells11091463 · Cited by 18
Kole, C., Charalampakis, N., Tsakatikas, S. A., Frountzas, M., Apostolou, K. G., & Schizas, D. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 16
Xu, H., Ma, Z., Mo, X., Chen, X., Xu, F., Wu, F., Chen, H., Zhou, G., Xia, H., & Zhang, C. (2022) · Journal of Cancer · doi:10.7150/jca.66020 · Cited by 17
Yao, W., Chen, X., Fan, B., Zeng, L., Zhou, Z., Mao, Z., & Shen, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1077605 · Cited by 16
Ueki, A., Yoshida, R., Kosaka, T., & Matsubayashi, H. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01153-1 · Cited by 18
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
Golan, T., Casolino, R., Biankin, A. V., Hammel, P. R., Whitaker, K. D., Hall, M. J., & Riegert‐Johnson, D. L. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231189127 · Cited by 16
Self-citationPlatinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Catalano, M., Lapucci, A., Nobili, S., Aquino, I. D. G., Vascotto, I. A., Antonuzzo, L., Villari, D., Nesi, G., Mini, E., & Roviello, G. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04604-w · Cited by 17
Murayama, A., & Marshall, D. C. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.12.011 · Cited by 18
Takashima, A., Alfonso, P. G., Manneh, R., Beşen, A. A., Hong, Y. S., Cuyle, P.-J. A., Yanez, P. E., Burge, M., Yoshino, T., Kim, T. W., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114036 · Cited by 17
Self-citationUnveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
Dominguez, A. A., Perz, M., Xu, Y., Cedillo, L. G., Huang, O. L., McIntyre, C. A., Vudatha, V., Trevino, J. G., Liu, J., & Wang, P. (2024) · Cancers · doi:10.3390/cancers16213564 · Cited by 17
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
Katona, B. W., Lubiński, J., Pal, T., Huzarski, T., Foulkes, W. D., Møller, P., Eisen, A. F., Armel, S. R., Neuhausen, S. L., Raj, R., et al. (2024) · Cancer · doi:10.1002/cncr.35666 · Cited by 16
Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Li, L., Kumar, A. K., Hu, Z., & Guo, Z. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200224102309 · Cited by 17
Abdallah, R., Taly, V., Zhao, S., Pietrasz, D., Bachet, J., Basile, D., Mas, L., Zaanan, A., Laurent‐Puig, P., & Taı̈eb, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102028 · Cited by 17
Kapacee, Z. A., Knox, J. J., Palmer, D. H., Blagden, S. P., Lamarca, Á., Valle, J. W., & McNamara, M. G. (2020) · Medical Oncology · doi:10.1007/s12032-020-01386-6 · Cited by 16
Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer
Liu, M., Liu, W., Qin, Y., Xu, X., Yu, X., Zhuo, Q., & Ji, S. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00179-x · Cited by 17
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress
Bezrookove, V., Patino, J. M., Nosrati, M., Desprez, P., McAllister, S. D., Soroceanu, L., Baron, A. D., Osorio, R. C., Kashani–Sabet, M., & Dar, A. A. (2021) · Cancers · doi:10.3390/cancers13174405 · Cited by 16
Seufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1771-6811 · Cited by 16
Personalized Systemic Therapies in Hereditary Cancer Syndromes
Mastrodomenico, L., Piombino, C., Riccò, B., Barbieri, E., Venturelli, M., Piacentini, F., Dominici, M., Cortesi, L., & Toss, A. (2023) · Genes · doi:10.3390/genes14030684 · Cited by 17
Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs
Lam, M. S., Olivier, T., Haslam, A., Tuia, J. E., & Prasad, V. K. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2306 · Cited by 18
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16
Smith, S. J., Meng, F., Lingeman, R. G., Li, C. M., Li, M., Boneh, G., Seppälä, T. T., Phan, T. X., Li, H., Burkhart, R. A., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.038 · Cited by 16
Tai, D. W.-M., Conroy, T., Lee, J. J. X., Chee, C. E., Hao, C., Wijaya, I., Aggarwal, S., Ueno, M., Jeung, H., Hashim, N. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105826 · Cited by 19
Yang, G., Yin, J., Ou, K., Du, Q., Ren, W., Jin, Y., Peng, L., & Yang, L. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01351-7 · Cited by 15
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
Molinaro, E., Andrikou, K., Gardini, A. C., & Rovesti, G. (2020) · Cancers · doi:10.3390/cancers12113346 · Cited by 15
Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies
Guo, J. A., Hoffman, H. I., Weekes, C. D., Zheng, L., Ting, D. T., & Hwang, W. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4712 · Cited by 14
Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
Sha, H., Gan, Y., Zou, R., Wu, J., & Feng, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.790967 · Cited by 15
NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer
Jung, K., Lee, S., Na, H. Y., Kim, J., Lee, J.-C., Hwang, J., Kim, J. W., & Kim, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-24732-2 · Cited by 15
State of the Art: ctDNA in Upper Gastrointestinal Malignancies
Labiano, I., Huerta, A. E., Arrazubi, V., Hernández-García, I., Mata, E., Gómez, D., Arasanz, H., Vera, R., & Alsina, M. (2023) · Cancers · doi:10.3390/cancers15051379 · Cited by 15
Shetu, S. A., James, N., Rivera, G., & Bandyopadhyay, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030124 · Cited by 15
Zhao, Z., Li, X., Wang, F., Xu, Y., Liu, S., Han, Q., Yang, Z., Huang, W., Yin, Z., Liu, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5871 · Cited by 15
Reißig, T. M., Tzianopoulos, I., Liffers, S.-T., Rosery, V., Guyot, M., Ting, S., Wiesweg, M., Kasper, S., Meister, P., Herold, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101539 · Cited by 15
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16
Genomics driven precision oncology in advanced biliary tract cancer improves survival
Kumar‐Sinha, C., Vats, P., Tran, N. H., Robinson, D. R., Gunchick, V., Wu, Y., Cao, X., Yu, N., Wang, R., Rabban, E., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100910 · Cited by 15
Zimmer, K., Kocher, F., Untergasser, G., Kircher, B., Amann, A., Baca, Y., Xiu, J., Korn, W. M., Berger, M. D., Lenz, H., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00409-5 · Cited by 15
Self-citationBiagi, J., Cosby, R., Bahl, M., Elfiki, T. A., Goodwin, R. A., Hallet, J. I., Hirmiz, K., & Mahmud, A. (2023) · Current Oncology · doi:10.3390/curroncol30070482 · Cited by 15
Byeon, S., du Toit‐Thompson, T., Gillson, J., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2023) · Cancer Medicine · doi:10.1002/cam4.6407 · Cited by 15
Hypoxic regulation of extracellular vesicles: Implications for cancer therapy
Yoo, S., Choi, S., Kim, I., & Kim, I. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.034 · Cited by 15
Li, Z., Luo, A., & Xie, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241915028 · Cited by 15
Huffman, B. M., Feng, H., Parmar, K., Wang, J., Kapner, K. S., Kochupurakkal, B. S., Martignetti, D. B., Sadatrezaei, G., Abrams, T. A., Biller, L. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2005 · Cited by 15
Vahabi, M., Comandatore, A., Centra, C., Blandino, G., Morelli, L., & Giovannetti, E. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.003 · Cited by 15
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer
LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16
Barzi, A., Weipert, C. M., Espenschied, C. R., Raymond, V. M., Wang‐Gillam, A., Nezami, M. A., Gordon, E. J., Mahadevan, D., & Mody, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1339302 · Cited by 15
The power and the promise of synthetic lethality for clinical application in cancer treatment
Liu, Q., Yang, Z., Tang, Q.-H., Wang, W.-E., Chu, D.-S., Ji, J.-F., Fan, Q.-Y., Jiang, H., Yang, Q.-X., Zhang, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116288 · Cited by 17
Clinical and molecular features of early onset pancreatic adenocarcinoma
Rémond, M., Smolenschi, C., Tarabay, A., Gelli, M., Fernandez-De-Sevilla, E., Mouawia, A., Cosconea, S., Tselikas, L., Barbe, R., Fuerea, A. C., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35135 · Cited by 15
Kirtonia, A., Pandya, G., Singh, A. P., Kumari, R., Singh, B., Kapoor, S., Khattar, E., Pandey, A. K., & Garg, M. (2025) · Life Sciences · doi:10.1016/j.lfs.2024.123364 · Cited by 14
PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
Patel, R., Fein, D. E. C., Bernabe, C., Do, K. J., & Saif, M. W. (2019) · Pancreas - Open Journal · doi:10.17140/poj-3-e011 · Cited by 15
Metadata
- Authors
- Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
- Affiliations
- Tel Aviv University (IL)
- From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 317-327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6810605
- OpenAlex
- W2947826965
- Cited by
- 2,302
- References
- 24
- Citations by year
- 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
- FWCI
- 129.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca (NA)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
- NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
